BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ:AKRX) today announced that it estimates second quarter 2008 net sales to exceed consensus estimates by approximately 15%. Revenue increases are a direct result of strength in our core business, primarily in vaccines.
